We claim:

1. A process for producing solid dosage forms, in which a moldable composition which comprises

a) 50 to 99.4% by weight of at least one crosslinked nonthermoplastic carrier,

b) 0.5 to 30% by weight of at least one adjuvant selected from thermoplastic polymers, lipids, sugar alcohols, sugar alcohol derivatives and solubilizers and

c) 0.1 to 49.5% by weight of at least one active ingredient,

is formed at a temperature at or above the softening point of the adjuvant, but at least 70°C, and subsequently cooled.

2. The process according to claim 1, where the composition comprises

a) 50 to 90% by weight of at least one crosslinked nonthermoplastic carrier,

b1) 5 to 30% by weight of at least one thermoplastic polymer,

b2) 0.5 to 20% by weight of at least one solubilizer,

c) 0.1 to 45.5% by weight of at least one active ingredient.

3. The process according to claim 1 or 2, where the crosslinked nonthermoplastic carrier is selected from crosslinked polyvinylpyrrolidone and crosslinked sodium carboxymethylcellulose.

4. The process according to any of the preceding claims, where the thermoplastic polymer is a homo- or copolymer of vinylpyrrolidone.

5. The process according to any of the preceding claims, where the sugar alcohol is selected from sorbitol, xylitol, mannitol, maltitol and the sugar alcohol derivative isomalt.

6. The process according to any of the preceding claims, where the lipid is selected from fatty acids, fatty alcohols, fats, waxes, mono- and diglycerides and phosphatides.

7. The process according to any of the preceding claims, where the solubilizer is selected from sorbitan fatty acid esters, polyalkoxylated fatty acid esters and polyalkoxylated ethers of fatty alcohols.

8. The process according to any of the preceding claims, where the active ingredient has a solubility in water at 25°C of less than 1 mg/ml.

9. The process according to any of the preceding claims, where the cooled composition is comminuted and compressed to the dosage form.